Edition:
United Kingdom

AVROBIO Inc (AVRO.OQ)

AVRO.OQ on NASDAQ Stock Exchange Global Select Market

15.77USD
23 May 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$15.77
Open
$15.54
Day's High
$16.56
Day's Low
$15.54
Volume
31,181
Avg. Vol
50,760
52-wk High
$53.70
52-wk Low
$11.85

Latest Key Developments (Source: Significant Developments)

Avrobio Reports Q1 Loss Per Share $0.72
Monday, 13 May 2019 

May 13 (Reuters) - AVROBIO Inc ::AVROBIO, INC. REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.QUARTERLY LOSS PER SHARE $0.72.SAYS PLANS TO OPEN U.S. CLINICAL TRIAL SITES FOR ITS ONGOING MULTI-COUNTRY FAB-201 TRIAL.Q1 EARNINGS PER SHARE VIEW $-0.72 -- REFINITIV IBES DATA.  Full Article

AVROBIO-Patients With Fabry Disease Are Currently Enrolling In AVRO-RD-01-201, Company's Phase 2 Clinical Trial (FAB-201)
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - AVROBIO Inc ::AVROBIO RECEIVES ORPHAN-DRUG DESIGNATION FROM THE U.S. FDA FOR AVR RD 01 FOR THE TREATMENT OF FABRY DISEASE.AVROBIO INC - PATIENTS WITH FABRY DISEASE ARE CURRENTLY ENROLLING IN AVRO-RD-01-201, COMPANY'S PHASE 2 CLINICAL TRIAL (FAB-201).  Full Article

Avrobio, Inc. QTRLY Loss Per Share $0.49
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - AVROBIO Inc ::AVROBIO, INC. REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.AVROBIO INC - EXPECTS CASH, CASH EQUIVALENTS AS OF SEPT 30, 2018, TO ENABLE IT TO FUND OPERATING EXPENSES AND CAPEX REQUIREMENTS INTO 2020.AVROBIO INC - ENDED QUARTER WITH $138.6 MILLION IN CASH AND CASH EQUIVALENTS.AVROBIO INC - QTRLY LOSS PER SHARE $0.49.  Full Article

Avrobio Gets No Objection To Clinical Trial Application From Health Canada
Monday, 1 Oct 2018 

Oct 1 (Reuters) - AVROBIO Inc ::AVROBIO RECEIVES NO OBJECTION TO CLINICAL TRIAL APPLICATION FROM HEALTH CANADA FOR AVR-RD-02 GENE THERAPY FOR GAUCHER DISEASE.AVROBIO INC - AVROBIO CONTINUES TO ADVANCE ITS PIPELINE OF GENE THERAPIES FOR LYSOSOMAL STORAGE DISORDERS.AVROBIO INC - COMPANY PLANS TO INITIATE PHASE 1/2 CLINICAL TRIAL IN PATIENTS WITH GAUCHER DISEASE IN 2019.  Full Article

AVROBIO Shares Debut About 54 Pct above IPO Price
Thursday, 21 Jun 2018 

June 21 (Reuters) - :AVROBIO INC SHARES OPEN AT $29.25 IN DEBUT ON THE NASDAQ VERSUS IPO PRICE OF $19.00/SHARE.  Full Article

Avrobio Announces Pricing Of Initial Public Offering
Thursday, 21 Jun 2018 

June 20 (Reuters) - AVROBIO Inc ::AVROBIO, INC. ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING.SAYS INITIAL PUBLIC OFFERING OF 5.25 MILLION COMMON SHARES PRICED AT $19.00PER SHARE.  Full Article